Live
Oncotype DX Breast Cancer Testing
£272,700
East Sussex Healthcare NHS TrustExact Sciences UK, Ltd.
services
Contract Details
- Tender Value
- £272,700
- Stage
- Live
- Published
- Awarded
Timeline
Awarded
Disclosed
Start
End
Description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Related Contracts
From This Buyer
- Cancer Chemocare System CIS Oncology
£29,953 ·
- Learning Management System
£128,963 ·
- BLOODHOUND/BLOOD360 SYSTEM
£54,886 ·
- Orthopaedic Hoods
£175,844 ·
From This Supplier
In This Category
- Planning System
£336,200 ·
- QOC907 09:00 2026-08-05 Thurston & Bury St Edmunds to In Toto Education, Ely, Cambs - AWARD
£162,336 ·
- Provision of Services for Change Capability Enablement and Portfolio Insights
£1,000,000 ·
- QNT019 09:00 2026-08-03 Haverhill to Polaris @ Newmarket Academy, Newmarket - AWARD
£68,400 ·
Ref: be83749f-55db-4eb4-b59b-40aa06ac75c4-886769 · Sourced from Contracts Finder
View source notice